PASG

Passage Bio, Inc.

PASG | News | $1.27 3.25% 3.15% 39K

(0.0% 1d) (-8.9% 1m) (23.8% 1y) (0.0% 2d) (7.9% 3d) (2.5% 7d) (-36.36% volume)
Earnings Calendar: 2024-03-04
Market Cap: $ 78,246,981
http://www.passagebio.com
Sec Filling | Patents | 20 employees

Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.

nervous system genetic msa treatment

add to watch list Paper trade email alert is off

Press-releases

Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Published: 2024-04-22 (Crawled : 11:00) - globenewswire.com
PASG | News | $1.27 3.25% 3.15% 39K

Health Technology

| 6.96% | O: 0.0% H: 3.48% C: -0.87%
genetic cell therapy

Passage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship Program
Published: 2024-03-05 (Crawled : 12:00) - globenewswire.com
PASG | News | $1.27 3.25% 3.15% 39K

Health Technology

| -28.07% | O: -5.85% H: 4.97% C: 4.35%
program

Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights
Published: 2024-03-04 (Crawled : 12:00) - globenewswire.com
PASG | News | $1.27 3.25% 3.15% 39K

Health Technology

| -27.22% | O: 1.78% H: 0.58% C: -0.58%
business financial results

Passage Bio to Participate in Upcoming Investor Conferences
Published: 2024-02-27 (Crawled : 12:00) - globenewswire.com
PASG | News | $1.27 3.25% 3.15% 39K

Health Technology

| -16.33% | O: -1.36% H: 9.66% C: 7.59%

Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Published: 2024-01-31 (Crawled : 17:00) - biospace.com/
PASG | News | $1.27 3.25% 3.15% 39K

Health Technology

| 28.13% | O: -1.56% H: 7.94% C: 3.7%
conference

Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities
Published: 2023-12-20 (Crawled : 12:00) - globenewswire.com
PASG | News | $1.27 3.25% 3.15% 39K

Health Technology

| 62.06% | O: 18.58% H: 0.26% C: -9.47%
pbft02 ftd-grn trial

Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Published: 2023-11-17 (Crawled : 22:00) - globenewswire.com
PASG | News | $1.27 3.25% 3.15% 39K

Health Technology

| Email alert Add to watchlist
nasdaq grant

Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
Published: 2023-11-13 (Crawled : 12:00) - globenewswire.com
PASG | News | $1.27 3.25% 3.15% 39K

Health Technology

| 105.0% | O: 6.48% H: 1.74% C: -6.09%
business financial results

Passage Bio to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference
Published: 2023-10-30 (Crawled : 11:00) - globenewswire.com
PASG | News | $1.27 3.25% 3.15% 39K

Health Technology

| 93.67% | O: 2.74% H: 5.59% C: 4.06%
conference immunology

Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2023-10-20 (Crawled : 21:00) - globenewswire.com
PASG | News | $1.27 3.25% 3.15% 39K

Health Technology

| Email alert Add to watchlist
nasdaq grants

See all